Bellicum's cancer drug trials on clinical hold, shares tumble

Bellicum Pharmaceuticals

30/01/2018 22:37

Jan 30 (Reuters) - Bellicum Pharmaceuticals Inc  BLCM.O  
said the U.S. Food and Drug Administration had placed a clinical 
hold on U.S. trials of the company's experimental cancer drug 
after three cases of brain disease linked to head trauma. 
    Shares of the Houston-based drug developer fell 48 percent 
to $5.26 in after-hours trading on Tuesday. 
    The company said the FDA had deemed the cases of brain 
disease as possibly being related to its cancer drug, BPX-501. 
 urn:newsml:reuters.com:*:nGNXOMTPNa 
    Bellicum said it would work closely with the FDA to address 
concerns. 
    The clinical hold does not affect another trial testing the 
same drug in Europe. 
    The company last year moved its planned submission of a 
European marketing application for the drug to 2019 from a 
previous expectation of mid-2018.  urn:newsml:reuters.com:*:nL4N1KV4XC 
 
 (Reporting by Akankshita; Editing by Sai Sachin Ravikumar) 
 ((Akankshita.Mukhopadhyay@thomsonreuters.com; within U.S. +1 
646 223 8780, outside U.S. +91 80 6749 0010; ; Reuters 
Messaging: 
akankshita.mukhopadhyay.thomsonreuters.com@reuters.net)) 
 
Keywords: BELLICUM PHARMS FDA/